A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

被引：1
|
作者：
Kristeleit, Rebecca Sophie
Brown, Nicholas F.
Hess, Dagmar
Joerger, Markus
Von Moos, Roger
Rodon, Jordi
Hierro, Cinta
Childs, Alexa
Stathis, Anastasios
Dimitrijevic, Sasa
Stumm, Michael
Herrmann, Richard
Sessa, Cristiana
Bize, Vincent
Hess, Viviane
Wicki, Andreas
机构：
[1] UCL, Inst Canc, London, England
[2] UCL, London, England
[3] Kantonsspital St Gallen, Eggersriet, Switzerland
[4] Cantonal Hosp, St Gallen, Switzerland
[5] VHIO, Barcelona, Spain
[6] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[7] PIQUR Therapeut AG, Basel, Switzerland
[8] Piqur Pharma, Basel, Switzerland
[9] Univ Hosp, Riehen, Switzerland
[10] IOSI, Bellinzona, Switzerland
[11] SAKK Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
[12] Univ Spital Basel, Basel, Switzerland
[13] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2592
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors
    Rodon, J.
    Infante, J.
    Burris, H.
    Tabernero, J.
    Ranson, M. R.
    Rouyrre, N.
    Duval, V.
    Silva, A.
    Hackl, W.
    Baselga, J.
    CANCER RESEARCH, 2010, 70
  • [32] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [33] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Dillon, Patrick M.
    Kabir, Sujan
    Mei, Jian
    Wade, Mark L.
    Yang, Huyuan
    Stapinski, Carl
    Foulks, Jason M.
    Warner, Steven L.
    Whatcott, Clifford
    Lebedinsky, Claudia
    Fu, Siqing
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [34] Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
    Makker, Vicky
    Recio, Fernando O.
    Ma, Ling
    Matutonis, Ursula
    Lauchle, Jennifer O'Hara
    Parmar, Hema
    Gilbert, Houston
    Wang, Yulei
    Koeppen, Hartmut
    Spoerke, Jill M.
    Lackner, Mark
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors
    Starks, David C.
    Rojas-Espaillat, Luis
    Meissner, Tobias
    Williams, Casey B.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 403 - 409
  • [36] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [37] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Joerger, Markus
    Calvo, Emiliano
    Laubli, Heinz
    Lopez, Juanita
    Alonso, Guzman
    de la Fuente, Elena Corral
    Hess, Dagmar
    Konig, David
    Perez, Vicky Sanchez
    Bucher, Christoph
    Jethwa, Sangeeta
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [38] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients (pts) with advanced solid tumors (ASTs).
    Vogelzang, Nicholas J.
    George, Ben
    Ashenbramer, Nissa
    Edenfield, William J.
    Richards, Donald
    Gross, Mitchell E.
    Fine, Gil D.
    Martinez, Pablo
    CANCER RESEARCH, 2022, 82 (12)
12345